Responding to the outcry over the news that one of its scientists produced genetically altered babies, the Chinese government last week issued draft regulations that would require national approval for clinical research involving gene editing and other "high-risk biomedical technologies." The need for new regulations was highlighted in November 2018 when He Jiankui, then of Southern University of Science and Technology in Shenzhen, China, announced that he had used the CRISPR genome-editing syst...
The implications of scientific breakthroughs are rarely faced up to in advance of their realization. Stem cell-derived human gametes, a disruptive technology in waiting, are likely to recapitulate this historic pattern absent active intervention. Herein we call for the conduct of thoughtful ante hoc deliberations on the prospect of stem cell-derived human gametes with an eye toward minimizing potential untoward post ho c regulatory or statutory impositions.
Eric Lander, Francoise Baylis, Feng Zhang, Emmanuelle Charpentier, Paul Berg and specialists from seven countries call for an international governance framework. Eric Lander, Francoise Baylis, Feng Zhang, Emmanuelle Charpentier, Paul Berg and specialists from seven countries call for an international governance framework.
KEY POINTS The response to the announcement in China on Nov. 25, 2018, of the “first clustered regularly interspaced short palindromic repeats [CRISPR] babies” is reminiscent of that surrounding the 1978 birth by in vitro fertilization of Louise Brown, the “first test-tube baby.” Will